TAXIS Pharmaceuticals is a privately held biopharmaceutical company dedicated to developing compounds to target the growing threat of antimicrobial resistance, including antibacterial and antiviral resistance. We are currently focused on antibiotic agents that employ novel mechanisms of action distinct from those currently in clinical use.
Our team’s expertise in discovery chemistry, combined with our spirit of innovation, allows us to quickly pinpoint promising compounds that exhibit the key properties required for a clinical drug candidate.
TAXIS has identified and patented twelve new classes of proprietary antibiotic agents, which are in various stages of preclinical development. We are developing our lead compound,TXA709, for the treatment of methicillin-resistant Staphylococcus aureus, more commonly known as MRSA, which is a major contributor to the global antibiotic resistance problem. We also are targeting other multidrug-resistant bacterial infections such as vancomycin-resistant Staphylococcus aureus (VRSA), vancomycin-resistant Enterococci (VRE), Clostridium difficile (C-diff), Pseudomonas aeruginosa, Escherichia coli, Klebsiella, Enterobacteriaceae and Acinetobacter baumannii.
TAXIS was founded in 2009. Our corporate headquarters is in Monmouth Junction, NJ.